Why you want IPI in combo with IMO 2025:
The CTLA-4 pathway is a critical regulator of T cell responses to tissues. The sharing of ligands with the stimulatory receptor CD28 establishes a rheostat, capable of tuning T cell responses. Accordingly, decreasing CTLA-4 function by antibody blockade, or in CTLA-4 genetic disorders, increases the availability of ligands for CD28 permitting the activation of potentially self-reactive T cells and altering Treg homeostasis. Furthermore, the high level expression of CTLA-4 on Treg and the emerging cell biology of this pathway continue to offer opportunities to stimulate or inhibit T cell responses.”
Further evidence in the paper that IPI is a Treg inhibitor....whooo-ah!